Related Experiment Video
Updated: Aug 12, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Acquired Hemophilia A In Adults: A Multicenter Study from Turkey
Eren Arslan Davulcu1, Zühal Demirci2, Umut Yılmaz3
1University of Health Sciences Bakırkoy Dr. Sadi Konuk Training and Research Hospital, Hematology Clinic, Istanbul, Turkey.
Acquired hemophilia A (AHA) is a rare autoimmune disorder affecting factor VIII (FVIII) activity. This study details Turkish AHA patient characteristics, management, and survival, showing a median overall survival of 154.97 months.
Area of Science:
- Hematology
- Autoimmune Diseases
- Rare Diseases
Background:
- Acquired hemophilia A (AHA) is a rare, life-threatening bleeding disorder caused by autoantibodies against factor VIII (FVIII).
- While often idiopathic, AHA can be associated with underlying conditions like pregnancy, malignancy, or infections.
- Effective management requires addressing acute bleeding and implementing immunosuppressive therapy.
Purpose of the Study:
- To investigate the clinical characteristics, management strategies, and survival outcomes of Acquired Hemophilia A patients in Turkey.
- To analyze demographic data, diagnostic parameters, treatment approaches, and complications in a Turkish AHA cohort.
- To provide insights into the long-term prognosis of AHA in a specific national context.
Main Methods:
- A multicenter retrospective study analyzing data from 29 Acquired Hemophilia A patients across eleven Turkish centers.
- Data collected included demographics, FVIII activity, inhibitor titers, bleeding severity, hemostatic and immunosuppressive treatments, and survival status.
- Statistical analysis of aPTT, FVIII, FVIII inhibitor, and hemoglobin levels, mixing tests, and treatment outcomes.
Main Results:
- The median FVIII activity was 0.7% and inhibitor titer was 32.6 BU, with severe bleeding in 44.8% of patients.
- Pregnancy, malignancy, and infections were the most common associated etiologies.
- Most patients (93%) received immunosuppression, with steroid, cyclophosphamide, and rituximab combinations being preferred. Median overall survival was 154.97 months.
Conclusions:
- Acquired Hemophilia A in Turkey presents with varying etiologies and requires prompt hemostatic and immunosuppressive treatment.
- The study highlights the importance of identifying underlying conditions and tailoring treatment for optimal outcomes.
- Turkish AHA patients demonstrate a relatively good long-term survival, underscoring the effectiveness of current management paradigms.
More Related Videos
09:14Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
13:12Quantitative Analyses of all Influenza Type A Viral Hemagglutinins and Neuraminidases using Universal Antibodies in Simple Slot Blot Assays
Published on: April 4, 2011
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Venous Thrombosis III: Interprofessional Care